Jaguar Health (JAGX) EBIAT (2016 - 2025)
Jaguar Health (JAGX) has disclosed EBIAT for 11 consecutive years, with -$7.2 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT rose 27.71% to -$7.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$38.6 million, a 0.8% decrease, with the full-year FY2024 number at -$39.3 million, up 6.32% from a year prior.
- EBIAT was -$7.2 million for Q3 2025 at Jaguar Health, up from -$10.6 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$7.2 million in Q3 2025 to a low of -$18.2 million in Q1 2022.
- A 5-year average of -$11.1 million and a median of -$10.6 million in 2025 define the central range for EBIAT.
- Peak YoY movement for EBIAT: tumbled 63.28% in 2021, then surged 42.51% in 2022.
- Jaguar Health's EBIAT stood at -$14.3 million in 2021, then soared by 42.51% to -$8.2 million in 2022, then fell by 13.08% to -$9.3 million in 2023, then fell by 9.94% to -$10.2 million in 2024, then rose by 29.22% to -$7.2 million in 2025.
- Per Business Quant, the three most recent readings for JAGX's EBIAT are -$7.2 million (Q3 2025), -$10.6 million (Q2 2025), and -$10.6 million (Q1 2025).